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Cardiac endothelium: 
More than just a barrier
geared towards being major regulators of myocardial function,(4) 
in both the physiological setting and the pathophysiological 
setting such as occurs with defi cient oxygen supply (ischaemia and 
hypoxia). Despite our awareness of the presence of these 
metabolically active cells in the heart, it is surprising to note that 
many studies continue to defi ne cardiac function in terms of(4) 
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Traditionally, the endothelium was viewed as a selectively per-
meable barrier between the circulating blood and underlying sub-
vascular interstitium; however, it is now known that the endo-
thelium has a far more intricate role: it is in fact a metabolically 
active organ, with endothelial cells acting as receptor-effector 
homeostats in the vasculature.(1,2) In this respect, endothelial cells 
secrete a variety of vaso-active and other bioactive molecules 
that regulate biological processes such as vascular tone, vascular 
infl ammation and haemostatis(1,3)  (Figure 1).
Although the role of endothelial cells in the maintenance of 
homeostasis in the general vascular system is well described, 
studies investigating their role in the myocardium, where they 
are numerically very well represented and often within diffusion 
distance from the cardiomyocytes, are less abundant. It is the 
proximity between cardiac endothelial cells and cardiomyocytes 
that is of particular importance, since it allows for paracrine 
communication between these cell types.(4,5) Therefore, cardiac 
endothelial cells are strategically positioned and functionally 
Cardiac endothelium consists of highly specialised endo-
thelial cells that are custom-designed to infl uence and 
regulate myocardial function. Various bioactive molecules, 
such as nitric oxide (NO) are released and given the short 
diffusion distance between especially the myocardial capil-
lary endothelial cells (cardiac micro vascular endothelial 
cells, CMECs) and adjacent cardiomyocytes, an ideal micro-
environment is created for paracrine communication. In 
this review paper, the relative role of the CMECs with 
regard to NO generation, the mechanisms of NO genera-
tion, and possible consequences of the released NO are 
described. Particular attention is given to these parameters 
under conditions of oxygen defi ciency, as this is one of the 
most common pathophysiological conditions affecting the 
heart.  SAHeart 2009; 6:174-185









FIGURE 1: The role of endothelium in vascular homeostasis. 
Various factors released by vascular endothelial cells result in 
equilibrium between a vasodilatory state (including anti-throm-
botic, anti-infl ammatory and anti-oxidant effects) and a vaso-
constrictory state (including pro-thrombotic, pro-infl ammatory 
and pro-oxidant effects). Vasodilatory effects are induced by 
factors such as nitric oxide (NO), endothelium-derived hyper-
polarising factor (EDHF) and prostacyclin, whereas vaso-
constrictory effects are induced by endothelin-1, thromboxane 
A2 (TXA2) and angiotensin II. When homeostasis is lost in favour 
of a net vaso-constrictory state, endothelial dysfunction will ensue. 



























cardiomyocyte physiology and function, coronary perfusion and 
neuroendocrine regulation.(5) 
Nitric oxide (NO) is one of the most important signalling mole-
cules produced and released by endothelial cells throughout the 
body via the constitutively expressed enzyme, endothelial NO 
synthase (eNOS).(6) Apart from its well known vascular effects, 
including vasodilation, anti-thrombosis and anti-infl ammation,(7,8,9) 
NO is known to protect the myocardium against ischaemic/
hypoxic injury.(10,11) The two best described NO-releasing cell 
types in the heart are the cardiac endothelial cells and cardio-
myocytes and since the former outnumber the latter by 3:1,(4,5) it 
is fair to assume that cardiac endothelial cells are the predomi-
nant source of cardiac NO and by implication, a putative source 
of NO-derived protection in the heart. It is therefore important 
and relevant that more studies investigate the role of cardiac 
endothelial cells as a source of NO in the normal and hypoxic/
ischaemic myocardium. Despite a plethora of studies on cardiac 
NO, data on the relative importance of NO derived from cardiac 
endothelial cells and cardiomyocytes are surprisingly scant.(12)
ENDOTHELIAL SUBTYPES IN THE HEART                  
Endothelial cells in the heart can be classifi ed based on their 
effects on, and proximity to, cardiomyocytes. Therefore, the endo-
thelial cells that line the myocardial capillaries (cardiac micro-
vascular endothelial cells, CMECs) and the endocardium (endo-
cardial endothelial cells, EECs) are collectively referred to as 
cardiac endothelium, as they are in close proximity to adjacent 
cardiomyocytes, and consequently have direct effects on cardio-
myocyte function.(5) Conversely, the endothelial cells that line the 
larger coronary arteries and veins are located further away from 
the cardiomyocytes. The coronary vascular endothelial cells, as 
they are called, exert indirect effects on myocardial function by 
controlling coronary perfusion.(5) The classifi cation of endothelial 
cells in the heart is shown in Figure 2. The EECs occupy a large 
cavity surface area to chamber volume ratio, which effectively 
allows for exposure to 100% of the circulating blood.(5,13) Given 
their exposure to the total amount of circulating humoral 
factors, the EECs are likely to act as a sensing system, in addition 
to their role as paracrine regulators of cardiomyocyte function.(13) 
Interestingly, in a study on quail embryos, it was found that EECs 
and cardiomyocytes initially develop from the same cardiac 
mesodermal region, although they eventually separate from each 
other.(14) In fact, in early embryonic development, the EECs are 
the only endothelial cell subtype present in the primitive spon-
gious heart tube, where they exist alongside the cardiomyocytes, 
in which, at around this time, the very fi rst contractions begin to 
appear.(13) The discovery that embryonic EECs release neuregulin, 
a member of the epidermal growth factor family, supported 
speculation of an obligatory role for EECs in cardiomyocyte  growth 
and development, especially since it was also(6) shown that the 
embryonic cardiomyocytes express the neuregulin receptors, 
ErbB2 and ErbB4.(15) 
In addition to its role as a sensing system of circulating blood and 
its contents and paracrine regulator of myocardial development 
and function, the endocardial endothelium is thought to represent 
a blood-heart barrier (BHB), similar to the well described blood-
brain endothelial barrier.(5) The subendocardial region contains 
highly excitable tissues including the Purkinje fi bre network and 
cardiomyocytes, which requires fi ne control of ionic concentra-
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FIGURE 2: Classifi cation of endothelial cells in the heart. The 
classifi cation is based on the proximity to, and direct paracrine 
infl uence on cardiomyocytes. Coronary vascular endothelial cells 
are situated in the larger coronary arteries and veins, and have 
no direct effects on cardiomyocyte function. Their biological 
effects are similar to those of endothelium elsewhere in the 
body (maintenance of vascular homeostasis). Conversely, the 
cardiac endothelial cells (endocardial endothelial cells and 
cardiac micro-vascular endothelial cells) have greater direct effects 
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tions and fl uxes via the BHB in order to maintain cardiac rhythmi-
city and mechanical performance.(5) Endocardial endothelial cells 
are well suited for this function through the presence of tight and 
gap junctions and through their distinct electrophysiological 
properties (high concentration of membrane ion channels and 
Na+ - K+ -ATPase).(5) EECs demonstrate a high concentration of 
eNOS expression in the Golgi bodies; furthermore, staining 
studies have shown that the Golgi bodies in EECs are signifi cantly 
larger in size than in other endothelial cell types.(13)  These proper-
ties point to a higher metabolic capacity in EECs compared to 
vascular endothelial cells.(5)  Compared to the EECs, the appear-
ance of the second cardiac endothelial cell subtype, the CMECs, 
is a relatively late event in the embryonic development of the 
heart, and their ability to infl uence cardiomyocyte function 
appears even later.(13) In this review paper, we will focus on the 
CMECs, their relation to the underlying cardiomyocytes and 
their role as an important source of NO in the heart.
THE UNIQUE STRUCTURAL AND FUNCTIONAL    
RELATIONS BETWEEN CARDIAC MICRO-
VASCULAR ENDOTHELIAL CELLS AND 
CARDIOMYOCYTES
Despite occupying the majority of the heart’s volume (∼ 75% of 
total tissue volume), and having a cell-to-cell mass ratio of 25:1 
compared to cardiac endothelial cells, the cardiomyocytes repre-
sent numerically less than 40% of the total cell number in the 
heart.(4,5) In fact, it is proposed that there are 3 cardiac endo-
thelial cells for every cardiomyocyte.(4) Anatomically, the architec-
ture of the heart promotes close proximity between the 
cardiomyocytes and the cardiac endothelial cells, particularly the 
CMECs. The myocardial capillary network is vast with capillaries 
located strategically around the cardiomyocytes allowing for each 
cardiomyocyte to be surrounded by 3-4 capillaries.(4) Despite the 
relatively large size of adult mammalian cardiomyocytes (∼10–100 
μm), the average intercapillary distance is ∼10–50 μm, which 
results in an intricate endothelial cell-cardiomyocyte assembly.(4,5,16) 
In view of this unique structural arrangement, each CMEC is 
within 1 μm distance from an underlying cardiomyocyte, which 
creates an ideal micro-environment for local transport and 
molecular communication.(5) The CMEC-cardiomyocyte arrange-
ment in the myocardium is depicted in Figure 3. (8) 
CARDIAC ENDOTHELIUM
Unlike the EECs, CMECs only receive ∼ 3-5% of the circulation, 
which, by implication, suggests that the relative concentration and 
pressure gradient of the humoral factors, rather than their total 
amount, would be more important for optimal paracrine 
communication (e.g. diffusion).(13) CMECs, as endothelial cells 
elsewhere in the body, release various bioactive molecules, the 
most important being NO, endothelin-1 (ET-1) and prostacyclin 
(PGI2).(4,5,13) Collectively, these CMEC-derived factors have direct 
effects on cardiomyocyte function, including cardiomyocyte con-
traction, rhythmicity and growth.(5) The molecular communica-
tion between CMECs and cardiomyocytes is bi-directional, which 
implies that the regulatory actions between these cell types are 
reciprocal. The paracrine communication between CMECs and 
cardiomyocytes is depicted in Figure 4.
CMEC-derived ET-1 acts in an autocrine and paracrine manner.(4) 
Autocrine effects are achieved when ET-1 binds to ETB receptors 
expressed on CMECs leading to NO and prostacyclin release.(4) 
Conversely, paracrine effects are observed when ET-1 binds to 
ETA receptors on cardiomyocytes resulting in myocardial con-
traction.(4) When released from vascular endothelial cells, prosta-
cyclin (PGI2) has anti-clotting and vasodilatory actions. However, 
in the myocardium, CMEC-derived PGI2 (and the more abundant 
EEC-derived PGI2) acts in a reciprocal fashion with NO: when 
endogenous PGI2 release is stimulated, the inotropic effects of 
FIGURE 3: The CMEC-cardiomyocyte arrangement in the 
myocardium. Cardiomyocytes (∼10-100 μm in size) are 
surrounded by myocardial capillaries (average intercapillary 
distance ∼10-50 μm). Each cardiomyocyte is associated with 
























NO are abolished while NO synthesis inhibition results in PGI2-
induced positive inotropic effects. (5) 
CMECs AND CARDIOMYOCYTES AS CELLULAR       
SOURCES OF MYOCARDIAL NO PRODUCTION
Both CMECs and cardiomyocytes are able to synthesise and 
release nitric oxide (NO), one of the most important chemical 
messengers in the heart;(5) NO is a key regulator of excitation-
contraction coupling in the cardiomyocytes and therefore of 
myocardial contractile function.(17) NO has also been shown to 
modulate heart rate, ß-adrenergic inotropic response, myocardial 
energetics and substrate metabolism.(12) NO effects are achieved 
via intracellular downstream mechanisms that have initially been 
thought to be mainly cyclic GMP (cGMP)-mediated, although it is 
now known that many of the effects of NO are cGMP-indepen-
dent.(17) The contractile effects of NO depend on the intra-
cellular location of its release and the end-targets of its signalling 
pathways, e.g. when NO signalling targets the L-type calcium 
channels in  cardiomyocytes, a decreased calcium current ensues 
which leads to attenuated ß-adrenergic receptor stimulated 
contraction.(17) In addition to its effects on myocardial contractile 
function and metabolism, NO is regarded as a potent cardio-
protective molecule, particularly in the context of ischaemia-
reperfusion injury and delayed ischaemic preconditioning.(10,11) 
In view of the major functional and protective effects that NO 
exerts in the heart, as well as its unique properties as an effi cient 
local messenger molecule (NO is a gas and free radical, and 
therefore highly diffusible and reactive),(18,19) it is imperative(10)  that 
more studies focus on the cellular sources of cardiac NO with 
particular emphasis on those cell types between which paracrine 
communication is likely. The enzymatic generation of NO in 
CMECs and cardiomyocytes is derived from the three most 
extensively described NO synthase (NOS) isoforms to date, viz. 
endothelial NOS (eNOS), inducible NOS (iNOS) and neuronal 
NOS (nNOS), all of which are to a larger or lesser extent 
expressed in both cell types.(20) Most authors agree that the 
constitutively expressed eNOS is associated with continuous NO 
production in relatively low quantities (< 100 nM) under physio-
logical, baseline conditions.(7,21) However, very few studies have 
quantifi ed and compared the relative expression of eNOS in 
CMECs and cardiomyocytes, although immune-histochemical 
studies have suggested higher expression in CMECs.(5,12) In a 
study using immune-fl uorescence and confocal microscopy, a 
signifi cant degree of non-uniformity was found with regard to 
the distribution of eNOS expression within the different cell 
subtypes of the cardiac endothelium: EECs showed greater eNOS 
staining compared to CMECs.(22)
iNOS (induction by factors such as infl ammatory cytokines), is 
expressed in both cardiac endothelial cells and cardiomyocytes, 
although the latter demonstrate a relatively higher iNOS / eNOS 
ratio than endothelial cells.(21) 
FIGURE 4: Paracrine communication between CMECs and cardiomyocytes. CMECs have direct paracrine effects on cardiomyocyte growth, 
contractile function and rhythmicity via the release of several bioactive molecules such as NO, endothelin-1, angiotensin II, prostacyclin and 
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iNOS releases NO in quantities much greater than eNOS (>1 
μm).(21) NO derived from iNOS is often associated with 
pathophysiological conditions; however the harmful effects are 
not due to NO per se, but rather the ability of excessive 
amounts of NO released by iNOS to react with superoxide to 
form the highly reactive peroxynitrite radical.(23) From a clinical 
point of view, excessive NO formation is an important mecha-
nism in the development of multiple organ failure (including 
myocardial depression) associated with sepsis.(24) NOS inhibition 
studies in large animal models have revealed inconclusive data as 
to whether any one specifi c NOS isoform is involved, rather 
suggesting that both iNOS and nNOS derived NO may be 
involved in the pathophysiological processes of septic shock.(24) 
Despite the uncertainty, administration of non-specifi c NOS inhi-
bitors have shown promising therapeutic effects by reversing 
sepsis-induced hemodynamic complications.(24)
In contrast, iNOS-derived NO may also be cardio-protective as 
it has convincingly been shown to be a mediator of protection 
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in ischaemic preconditioning.(10,11) There is not much data avail-
able on the role of nNOS in endothelial cells, although more 
and  more evidence is appearing that demonstrates a signifi cant 
expression of, and role for nNOS in cardiomyocytes.(17)
ENOS IN CMECs: MANY QUESTIONS REMAIN              
It is widely accepted that eNOS is the predominant enzymatic 
source of NO in endothelial cells, including the CMECs. As 
explained earlier, CMECs do exhibit positive staining for eNOS, 
albeit to a lesser degree compared to other forms of cardiac 
endothelial cells such as the EECs.(22) Given the potential import-
ance of reciprocal cellular cross-talk between CMECs and the 
underlying cardiomyocytes, it is surprising that the majority of 
studies in this fi eld rely on semi-quantitative staining techniques 
to assess the relative expression of eNOS in these two cell types. 
It is also apparent from the literature that very few studies make 
use of direct intracellular NO-measurement tools to quantify, or 
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FIGURE 5: Direct intracellular NO measurement by fl ow cytometric analysis of DAF-2/DA fl uorescence. CMECs are pre-treated with the NO-
specifi c probe, DAF-2/DA (100 μm) which remains present for the duration of the experiments, after which the probe is washed out and samples 
analysed by fl ow cytometry (Becton Dickinson FACSCalibur® Analyzer with the aid of Cellquest® Version 3.3 software. )
Forward scatter
Gated Population
A: The cell population of interest is gated based on the forward scatter 
(cell size) and side scatter (cell granularity) properties of the CMECs, 
indicated by the blue circle on the scatter plot. 
B: The fl uorescence intensity (emitted when DAF-2/DA reacts with 
NO) of the gated population is measured in the FL-1H (green 
fl uorescence) channel. From the histogram it is clear that there is an 
increase in fl uorescence intensity in hypoxic CMECs compared to 
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C: Expression of total eNOS protein (measured by Western blotting 
analysis; molecular weight 140 kDa) in normoxic CMECs and cardio-
myocytes. CMECs expressed 22 times more eNOS protein than 
cardiomyocytes.
B: Bar graph showing NO production in CMECs and cardiomyocytes 
comparing data on a cell-to-cell basis. Under normoxic conditions, 
CMECs produced 26 times more NO than an equal number of 
cardiomyocytes and in hypoxia; CMECs produced 52 times more 
NO than cardiomyocytes. 
type.(25) Without direct, quantitative measurements, it will always 
be diffi cult to reach any substantial conclusions regarding the 
existence or importance of paracrine NO communication be-
tween CMECs and cardiomyocytes both with regard to their ability 
to generate NO (i.e. eNOS measurements) and the amount of 
NO they produce (i.e. direct NO-specifi c measurements).(26) In 
addition to the hiatus that exists regarding the relative expression 
of eNOS protein, few studies have investigated the regulation of 
eNOS activity (via phosphorylation) in CMECs; in fact, the role 
of eNOS activation by phosphorylation is under-researched in 
heart tissue as a whole.(27) One of the most common patho-
physiological conditions affecting the myocardium is the develop-
ment of reduced oxygen supply (ischaemia and hypoxia). It is 
now widely accepted that myocardial NO content increases 
shortly after the onset of ischaemia/hypoxia, and that this 
increase is partly due to NOS activation; however, considerable 
uncertainty still remains regarding which NOS isoforms are 
involved.(21,28) Apart from NOS involvement in hypoxia/ischaemia-
induced NO production, other NOS-independent sources are 
also implicated, such as the reduction of nitrites to NO.(29) 
NO PRODUCTION IN CMECS                                      
In order to gain more knowledge on the role of CMECs in the 
myocardium with regard to NO production, we studied intra-
cellular NO generation in a model of cultured CMECs derived 
from adult rat hearts (and compared fi ndings with those obtained 
in isolated cardiomyocytes). NO production was measured in 
normoxic and hypoxic CMECs using a fl uorescence-based detec-
tion technique previously developed in our laboratory (DAF-2/
DA: NO-specifi c fl uorescent probe)(25,26) (Figure 5).
Most authors agree that myocardial NO levels increase during 
hypoxia [Schulz 2004] and our model of cultured CMECs also 
responded in this fashion by demonstrating up to 3.3-fold increase 
in intracellular NO production(26) (Figure 6A). This is in agreement 
with other studies that investigated hypoxia-induced NO production 
in endothelial cells obtained from the heart, viz. coronary artery, 
arteriolar and micro-vascular endothelial cells.(30,31,32) Interestingly, 
not all endothelial cell studies observe hypoxia-induced increases 
in NO production: one study on human saphenous vein endo-
thelial cells showed a 74% reduction in NO levels after exposure 
FIGURE 6: NO production and eNOS protein expression in CMECs. 
(Blots and graphs reproduced with the permission of FASEB Journal and obtained from: 
Strijdom H, Jacobs S, Hattingh S et al. Nitric oxide production is higher in cardiac micro-vessel 
endothelial cells than ventricular cardiomyocytes in baseline and hypoxic conditions: a 
comparative study. FASEB J 2006;20(2): 314-316.)
Normoxic 
Myocytes
A: Bar chart depicting NO production under normoxic and hypoxic 
conditions, with and without the administration of NOS inhibitors, 
NW-nitro-L-arginine methyl ester (L-Name, 50 μM; non-specifi c NOS 
inhibitor) and S-methylisothiourea (SMT, 100 μm; iNOS-specifi c 
inhibitor). CMECs subjected to hypoxia (hypoxic pelleting) showed 
increased NO production, L-Name signifi cantly reduced NO produc-
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to hypoxia.(33) These discrepancies may be explained by differences 
in the endothelial cell subtype investigated and the protocols used.
Of particular interest to us was to confi rm previously held asser-
tions that CMECs generate more NO than cardiomyocytes. In 
order to achieve this objective, it was necessary to assess NO 
production with a technique that allowed for direct measure-
ment of intracellular NO levels, since opinions at the time were 
mainly based on data obtained from indirect immunohistochem-
ical and fl uorescence based labelling studies directed at eNOS 
protein.(5,12) The fl ow cytometry-based NO-detection technique 
developed in our laboratory made it possible to gate populations 
of identical cell numbers (See Figure 5 for explanation of fl ow 
cytometry technique), which enabled the investigator to calculate 
and compare data on a cell-to-cell basis. Our fi ndings validated 
the prevailing belief that CMECs generate more NO than 
cardiomyocytes: the CMECs produced 26 times more NO/cell 
than cardiomyocytes under normoxic conditions (Figure 6B). 
Further validation for the NO data was found when we compared 
normoxic eNOS protein expression (measured by Western 
blotting analysis) in the two cell types: baseline eNOS expres-
sion was 22 times greater in the CMECs on a cell-to-cell basis 
(Figure 6C). When subjected to an identical hypoxia protocol, 
CMECs generated 52 times more NO/cell than cardiomyo-
cytes(26) (Figure 6B). To our knowledge, this was the fi rst study 
to directly measure and compare intracellular NO production in 
these two cardiac cell types. The importance of these fi ndings lies 
in the fact that it creates a better understanding of the possible 
nature of the in vivo myocardial NO dynamics. The CMECs, of 
all the endothelial cell types in the heart, are in closest proximity 
to the largest portion of cardiac muscle cells, and given the fact 
that there is at least one CMEC for every cardiomyocyte, there 
is a high probability that the cardiomyocytes could be recipients 
of excess NO released by the CMECs (termed “spill-over 
diffusion”).(26) Preliminary studies in our laboratory (data not 
shown) have suggested that there is a net uptake of NO by 
cardiomyocytes when co-cultured with CMECs, however, more 
research is required to confi rm this phenomenon as well as to 
establish the biological effects of spill-over diffusion, not only 
under normoxic conditions, but more specifi cally in a hypoxic 
environment. 
CARDIAC ENDOTHELIUM
REGULATION AND ACTIVATION OF ENOS IN               
CMECS
Following the observation that NO generation increases after 
exposure to hypoxia, we wanted to determine the source of 
such an increase, especially since this has not yet been well 
established in CMECs. Our primary focus was on eNOS and 
iNOS as putative enzymatic sources of NO production. Initially, 
we inhibited eNOS and iNOS pharmacologically during hypoxia 
with L-NAME (relatively non-specifi c NOS inhibitor) and SMT 
(iNOS-specifi c inhibitor) to tease out NOS isoform involvement. 
Results suggested a partial contribution from eNOS, but that 
iNOS did not seem to be involved at all(26) (Figure 6A). In fact, 
subsequent Western blotting measurements confi rmed the iNOS 
inhibition data, as it revealed that the iNOS protein was not 
expressed in our CMEC model at all.(28)
From the above data, it seems that CMECs (and endothelial cells 
from the larger blood vessels in the heart as demonstrated by 
other authors) respond to hypoxia by increasing their NO 
production, and that this is partly mediated by increased eNOS 
activity. On all accounts, the iNOS isoform does not seem to be 
involved in our model of CMECs. It is well known that data 
obtained from studies using pharmacological inhibitors can be 
notoriously misleading, since many inhibitors are non-specifi c. In 
addition, existing data on the regulation of eNOS protein expres-
sion and activation by phosphorylation in CMECs (and the whole 
heart for that matter) are scant,(27) particularly with regard to 
the role of hypoxia as a putative activating stimulus.(12,34) 
Phosphorylation of eNOS at the Ser 1177 residue is the best 
described and probably most important mechanism of eNOS 
activation.(35,36) We therefore, as a next step, repeated the 
normoxia and hypoxia investigations and measured total eNOS 
expression and activated eNOS (phosphorylated eNOS at 
Ser 1177) levels by Western blotting analyses.(28) The data showed 
that total eNOS protein expression increased by 4-fold in 
CMECs exposed to 18 h of low PO2 incubation (see legend of 
Figure 7 for a description of this hypoxia protocol), and that 
activated levels of eNOS increased by 5-fold(28) (Figure 7A). The 
relative activated/total eNOS increase was therefore 1.25-fold, 
implying that the activated levels of eNOS increased by a greater 
margin than the total protein in this hypoxia protocol. In CMECs 
















































FIGURE 7: Total eNOS protein and activated eNOS (phosphorylated eNOS at Ser 1177) in CMECs exposed to two different hypoxia protocols. In 
the fi rst protocol, CMECs remained in culture and incubated in low-serum culture medium for 18 h under a low PO2 atmosphere (O2: 1%). In the 
second protocol, CMECs were removed from culture by trypsinisation and the isolated cells were subsequently pelleted and covered with a mineral 
oil layer (hypoxic pelleting) for 60 min. 
A: Western blotting data from cultured cells exposed to 18 h low PO2 incubation showing a 4-fold increase in total eNOS protein expression and 


































































B: Western blotting data from isolated CMECs exposed to hypoxic pelleting for 60 min, showing a 2.8-fold increase in total eNOS protein expression 
and 2.6-fold increase in phosphorylated eNOS levels respectively. *: p < 0.05 vs. control. 
Total eNOS
(Blots and graphs reproduced with the permission of Springer Verlag and obtained from: Strijdom H, Friedrich SO, Hattingh S, et al. Hypoxia-induced regulation of nitric 
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a description of this protocol), total eNOS protein increased by 
2.8-fold, and activated levels of eNOS by 2.6-fold(28) (Figure 7B). 
In this instance, it seems as if the increase in activated eNOS 
was largely determined by the upregulation of eNOS protein, as 
the activated/total eNOS ratio was ∼ 1. Our fi ndings therefore 
point to a pivotal role for eNOS in hypoxia, and it seems that 
the increased NO production in CMECs is mainly derived from 
eNOS – either due to upregulation of eNOS protein or due to 
a relative increase in activated eNOS levels (via phosphorylation 
at the Ser 1177 residue). These results dispel the traditionally 
held notion that eNOS is predominantly associated with 
maintenance of physiological function. However, some studies 
(mainly in endothelial cells of non-cardiac origin) showed opposite 
effects. As mentioned previously, in saphenous vein and pulmon-
ary artery endothelial cells, hypoxia induced down regulation of 
eNOS protein and in human umbilical vein endothelial cells, 
a 40-60% reduction in eNOS mRNA levels was observed(37) 
suggesting that endothelial cell responses to hypoxia are seem-
ingly determined by their anatomical location, with endothelial cells 
of cardiac origin generally tending to increase their eNOS protein 
content and activation and produce larger amounts of NO. 
MECHANISMS OF eNOS ACTIVATION IN CMECs         
At this point, it was clear that hypoxia induced NO production 
mainly via eNOS, with apparently no participation from iNOS. 
However, the upstream mechanism through which eNOS is 
phosphorylated and therefore activated in CMECs remained 
unclear.(28) One possibility was that the phosphatidylinositol-3 
kinase (PI-3K)/protein kinase B (PKB/Akt) pathway is switched on 
during hypoxia, with subsequent phosphorylation of eNOS by 
activated PKB/Akt. Although this eNOS activating mechanism 
was observed in porcine coronary endothelial cells(30) it had not 
been described in CMECs before. Therefore, we examined the 
effect of hypoxia on PKB/Akt, and the fi ndings showed that total 
PKB/Akt protein expression remained unchanged in hypoxic 
CMECs compared to normoxic controls; however, activated PKB/
Akt (phosphorylated PKB/Akt at Ser 473) increased by 1.7-fold 
to 3-fold, depending on the hypoxia protocol (Figure 8A). There-
fore, in both instances, the relative activated/total PKB/Akt ratio 
indicated that the increase in activated levels was greater than 
the increases observed in total protein expression. The fact that 
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activated levels of both eNOS and PKB were signifi cantly increased 
after identical periods of hypoxia was a promising fi nding sugges-
tive of a possible mechanistic link between the two. Our hypo-
thesis was further validated when we inhibited the PI-3K – PKB/
Akt pathway during hypoxia and observed a signifi cant reduction 
in NO production compared to untreated hypoxic cells (Figure 8B).
The above data suggest that hypoxia induces increased amounts 
of NO in CMECs, which are mainly generated by activated 
eNOS, which seems to be consequential to phosphorylation of 
its Ser 1177 residue by activated PKB/Akt. However, the mole-
cular mechanism by which hypoxia switches on the PI3-K –PKB/
Akt pathway upstream from eNOS is unknown. Interestingly, in 
separate experiments, we observed a similar PI3-K - PKB/Akt – 
eNOS – NO mechanism at play in hypoxic cardiomyocytes; 
however, in the latter cell type we suspect there to be a greater 
contribution from iNOS than in CMECs, as iNOS protein was 
expressed in our cardiomyocytes and iNOS-specifi c inhibition 
signifi cantly reduced NO production.(26,28) It has to be noted that 
although eNOS seems to be the major role-player in the pro-
duction of NO in hypoxic CMECs, inhibition of the enzyme did 
not completely abolish NO production.(26) As iNOS was not 
involved in our model of CMECs, and a signifi cant role for nNOS 
in CMECs has yet to be found, the possibility of a contribution 
from NOS-independent sources of NO, such as acidosis-induced 
reduction of nitrites, cannot be excluded.(29)
CONCLUSION                                                                          
In this review paper, we described the importance of the endo-
thelial cells that line the capillaries of the myocardium. Collect-
ively, these endothelial cells form a unique and functionally distinct 
subtype, with one factor that distinguishes them from any other 
endothelial cell subtype in the heart: location. Positioned within 
1 μm from the functional units of the heart’s contractile machinery, 
the cardiomyocytes, the CMECs are in an ideal position to infl u-
ence and regulate myocardial function. This is achieved through 
the release of a variety of bioactive molecules. Of particular 
interest, and emphasised in this paper, is the role of CMECs as 
suppliers of NO, one of the most important chemical mes-
sengers in the body. The unique properties of NO as a medi-








































FIGURE 8: Establishing a role for the PI3-K – PKB/Akt pathway in hypoxia-induced eNOS activation. 
A:  Western blotting data from isolated CMECs exposed to hypoxic pelleting for 60 min, showing unchanged total PKB/Akt protein expression and 



























































B: Bar chart depicting NO production in isolated CMECs exposed to 60 min hypoxic pelleting with or without administration of the PI3-K – PKB/Akt 
pathway inhibitor, Wortmannin (100 nM). Wortmannin administration resulted in a signifi cant reduction in NO production in hypoxic CMECs. 
*: p < 0.05 vs. untreated hypoxia. 
(Blots and graphs reproduced with the permission of Springer Verlag and obtained from: Strijdom H, Friedrich SO, Hattingh S, et al. Hypoxia-induced regulation of nitric 
oxide synthase in cardiac endothelial cells and myocytes and the role of the PI3-K/PKB pathway. Mol Cell Biochem 2009;321(1-2): 23-35.)
* *
*
Control Hypoxia Control Hypoxia
Control Control +Wort Hypoxia Hypoxia +Wort
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free radical nature, allowing it to diffuse freely from one cell to 
another and exert a high degree of reactivity with a host of 
target molecules.(27) It is therefore not an exaggeration to describe 
NO as the ideal chemical messenger! The importance of NO is 
further underlined by its role as a potent cardio-protective agent, 
and a plethora of evidence exists showing just how effi cient 
NO is in protecting the myocardium against damage caused by 
ischaemia, ischaemia-reperfusion and hypoxia.(10,11)
A crucial shortcoming in literature, however, has been the lack of 
studies that: 
directly and quantitatively measure intracellular production 
of NO, 
explore the mechanisms underlying NO generation, and 
compare the above fi ndings in CMECs and cardiomyocytes. 
In the absence of such knowledge, there is no foundation on 
which further studies can be built that could ultimately explain, 
and not merely speculate on, the nature and biological effects of 
CMEC cardiomyocyte cross-talk, especially with regard to NO 
as messenger molecule.
In our studies, we attempted to address some of these 
shortcomings.
We described the interesting relation between CMECs and 
cardiomyocytes, both known to be NO-generating cell types, 
with regard to the amount of NO produced by each. Our 
investigations, the fi rst to directly measure and compare intra-
cellular NO levels in these two cell types on a cell-to-cell basis, 
validated the previously held assumption that CMECs are indeed 
greater producers of NO and these data were further supported 
when it became evident that the eNOS content also followed a 
similar trend: NO production was ~ 26 times higher per cell and 
eNOS expression ~ 22 times higher in CMECs per cell compared 
to cardiomyocytes under normoxic conditions. Furthermore, 
our fi ndings confi rmed existing data in the literature with regard 
to NO production during hypoxia showing signifi cant increases 
in the hypoxic cells. In fact, hypoxia managed to further widen 
the gap between the amount of NO produced in CMECs and 




the interstitium by hypoxic CMECs. We have also identifi ed the 
PI-3K - PKB/Akt pathway as a likely upstream activating mecha-
nism of eNOS-derived NO production during hypoxia, described 
for the fi rst time in CMECs.
In view of our fi ndings and applying the laws of simple diffusion, it 
is likely that a NO concentration gradient exists from the CMECs 
to the cardiomyocytes, and that excess CMEC-derived NO may 
diffuse into cardiomyocytes (“spill-over diffusion”) with as yet 
undetermined effects. These data have important implications 
for our understanding of the paracrine communication between 
CMECs and cardiomyocytes in which NO is the messenger. It is 
generally thought that the paracrine effects of NO released by 
CMECs are associated with sustaining various physiological func-
tions in cardiomyocytes, such as contractility/relaxation, growth 
and development and other metabolic functions. However, it 
may not be as simple as that, since our data suggest there might 
be a larger NO concentration gradient directed towards the 
cardiomyocytes than previously thought, particularly under 
hypoxic conditions. One should also bear in mind that hypoxic 
cardiomyocytes themselves produce increased amounts of NO, 
in addition to the CMEC-derived NO that diffuses from the 
interstitium, which may lead to the accumulation of relatively 
high concentrations of NO in these cells. Whether the spill-over 
diffusion of excess NO into the cardiomyocytes is benefi cial or 
harmful, remains unanswered and further investigations are 
necessary. From previous data, however, it is known that large 
amounts of NO result in the generation of the potentially cyto-
toxic radical, peroxynitrite and its downstream derivatives,(23) 
which should be considered when assessing the impact of spill-
over diffusion into the cardiomyocytes.
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